We are live on ! Find out more

BioNTech

BNTX

Market cap $24.4B

96.96 USD

+4.90

5.32%

At close Updated Oct 9, 4:00 PM EDT

Pre-market

After hours

97.20

+0.24

0.25%

1 day

5.32%

5 days

0.23%

1 month

-1.19%

3 months

4.28%

6 months

5.41%

Year to date

0.28%

1 year

-7.2%

5 years

-60.1%

10 years

580.9%

About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Employees: 7,807

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 41.3%

Neutral 32.6%

Negative 26.1%

24/7 Wall Street

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect.

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

The Motley Fool

BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?

BioNTech now has more than 25 phase 2 and phase 3 oncology trials underway, with 15 phase 3 trials targeted by the end of 2026. Pumitamig is being tested across lung, breast, gastric, and kidney cancers, giving the drug multiple paths to commercial success.

BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?

24/7 Wall Street

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up

24/7 Wall Street

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company's messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset has yet to be presented publicly.

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

24/7 Wall Street

Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water

Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company's cancer vaccine pipeline over the valuation warning.

Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water

Zacks Investment Research

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

BioNTech to shutter sites in Germany, Singapore as no buyers emerge

German COVID‑19 vaccine maker BioNTech said on Monday it would close sites in Germany and Singapore because ‌it failed to find buyers after pivoting away from pandemic-era manufacturing.

BioNTech to shutter sites in Germany, Singapore as no buyers emerge

The Motley Fool

Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?

BioNTech recently experienced a clinical trial failure, followed by a clinical success several weeks later. The company's deep pipeline could enable it to launch brand-new, lucrative products over the next few years.

Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?

The Motley Fool

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback.

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

24/7 Wall Street

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at

Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher

See News Rankings

Price charts implemented using Lightweight Charts™